［1］ FORNER A,REIG M,BRUIX J.Hepatocellular carcinoma［J］.Lancet,2018,391(10127):1301-1314.
［2］ LLOVET JM,ZUCMAN-ROSSI J,PIKARSKY E,et al.Hepatocellular carcinoma［J］.Nat Rev Dis Primers,2016,2:16018.
［3］ KOUNDOUROS N,POULOGIANNIS G.Reprogramming of fatty acid metabolism in cancer［J］.Br J Cancer,2020,122(1):4-22.
［4］ LI Z,ZHANG H.Reprogramming of glucose,fatty acid and amino acid metabolism for cancer progression［J］.Cell Mol Life Sci,2016,73(2):377-392.
［5］ CURRIE E,SCHULZE A,ZECHNER R,et al.Cellular fatty acid metabolism and cancer［J］.Cell Metab,2013,18(2):153-161.
［6］ NAKAGAWA H,HAYATA Y,KAWAMURA S,et al.Lipid metabolic reprogramming in hepatocellular carcinoma［J］.Cancers(Basel),2018,10(11)：447.
［7］ CARRACEDO A,CANTLEY LC,PANDOLFI PP.Cancer metabolism:fatty acid oxidation in the limelight［J］.Nat Rev Cancer,2013,13(4):227-232.
［8］ BUDHU A,ROESSLER S,ZHAO X,et al.Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes［J］.Gastroenterology,2013,144(5):1066-1075.e1.
［9］ YAMASHITA T,HONDA M,TAKATORI H,et al.Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma［J］.J Hepatol,2009,50(1):100-110.
［10］ LIN J,YANG R,TARR PT,et al.Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP［J］.Cell,2005,120(2):261-273.
［11］ PICCININ E,PERES C,BELLAFANTE E,et al.Hepatic peroxisome proliferator-activated receptor γ coactivator 1β drives mitochondrial and anabolic signatures that contribute to hepatocellular carcinoma progression in mice［J］.Hepatology,2018,67(3):884-898.
［12］ BELORIBI-DJEFAFLIA S,VASSEUR S,GUILLAUMOND F.Lipid metabolic reprogramming in cancer cells［J］.Oncogenesis,2016,5（1）:e189.
［13］ HSU SH,WANG B,KOTA J,et al.Essential metabolic,anti-inflammatory,and anti-tumorigenic functions of miR-122 in liver［J］.J Clin Invest,2012,122(8):2871-2883.
［14］ LIU X,LIANG Y,SONG R,et al.Long non-coding RNA NEAT1-modulated abnormal lipolysis via ATGL drives hepatocellular carcinoma proliferation［J］.Mol Cancer,2018,17(1):90.
［15］ ZARE M,PANAHI G,KOUSHKI M,et al.Metformin reduces lipid accumulation in HepG2 cells via downregulation of miR-33b［J］.Arch Physiol Biochem，2022,128（2）：330-340.
［16］ DA SILVEIRA MB,PANSA CC,MALASPINA O,et al.The functional activity of the miR-1914-5p in lipid metabolism of the hepatocarcinoma cell line HepG2:A potential molecular tool for controlling hepatic cellular migration［J］.Mol Biol Rep,2021,48(4):3463-3474.
［17］ ZHAO G,DONG L,SHI H,et al.MicroRNA-1207-5p inhibits hepatocellular carcinoma cell growth and invasion through the fatty acid synthase-mediated Akt/mTOR signalling pathway［J］.Oncol Rep,2016,36(3):1709-1716.
［18］ LI D,CHENG M,NIU Y,et al.Identification of a novel human long non-coding RNA that regulates hepatic lipid metabolism by inhibiting SREBP-1c［J］.Int J Biol Sci,2017,13(3):349-357.
［19］ WU H,NG R,CHEN X,et al.MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway［J］.Gut,2016,65(11):1850-1860.
［20］ ZHANG H,FENG Z,HUANG R,et al.MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1［J］.Int J Oncol,2014,45(5):2143-2152.
［21］ CUI M,WANG Y,SUN B,et al.MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1(ACSL1)mRNA［J］.Biochem Biophys Res Commun,2014,444(2):270-275.
［22］ CUI M,XIAO Z,WANG Y,et al.Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway［J］.Cancer Res,2015,75(5):846-857.
［23］ CUI M,XIAO Z,SUN B,et al.Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4［J］.Biochem Biophys Res Commun,2014,445(3):651-655.
［24］ XU G,YANG F,DING CL,et al.Small nucleolar RNA 113-1 suppresses tumorigenesis in hepatocellular carcinoma［J］.Mol Cancer,2014,13:216.
［25］ GUO J,FANG W,SUN L,et al.Ultraconserved element uc.372 drives hepatic lipid accumulation by suppressing miR-195/miR4668 maturation［J］.Nat Commun,2018,9(1):612.
［26］ VANNI S.Intracellular lipid droplets:From structure to function［J］.Lipid Insights,2017,10:1178635317745518.
［27］ KOIZUME S,MIYAGI Y.Lipid droplets:A key cellular organelle associated with cancer cell survival under normoxia and hypoxia［J］.Int J Mol Sci,2016,17(9):1430.
［28］ BAENKE F,PECK B,MIESS H,et al.Hooked on fat:The role of lipid synthesis in cancer metabolism and tumour development［J］.Dis Model Mech,2013,6(6):1353-1363.
［29］ ZHANG Q,MA XF,DONG MZ,et al.MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in Huh-7 cell line［J］.Lipids Health Dis,2020,19(1):76.
［30］ YUAN P,MU J,WANG Z,et al.Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation［J］.Cell Death Dis,2021,12(4):361.
［31］ LIU Y,LYU LL,WEN D,et al.MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming［J］.J Hematol Oncol,2020,13(1):12.
［32］ YAN S,YANG XF,LIU HL,et al.Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases:An update［J］.World J Gastroenterol,2015,21(12):3492-3498.
［33］ GREVENGOED TJ,KLETT EL,COLEMAN RA.Acyl-CoA metabolism and partitioning［J］.Annu Rev Nutr,2014,34:1-30.
［34］ AROUS C,NAIMI M,VAN OBBERGHEN E.Oleate-mediated activation of phospholipase D and mammalian target of rapamycin(mTOR)regulates proliferation and rapamycin sensitivity of hepatocarcinoma cells［J］.Diabetologia,2011,54(4):954-964.
［35］ VINCIGUERRA M,CARROZZINO F,PEYROU M,et al.Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN［J］.J Hepatol,2009,50(6):1132-1141.
［36］ LI H,CHEN Z,ZHANG Y,et al.MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis［J］.Cancer Lett,2021,519:161-171.